# Kairos Ventures

> Kairos Ventures is a VC fund backing Biotechnology and Health Care. See 63 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Beverly Hills, United States
- Total investments: 63
- Last investment: Jul 2026
- Lead investor: 33%
- Fund size: $250M
- Last fund: Nov 2019
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company-beta/7933611/
- X (Twitter): https://twitter.com/TweetKairosVC
- Website: http://www.kairosventures.com
- Facebook: https://www.facebook.com/pg/kairosvc

Kairos Ventures is a VC fund in Beverly Hills focused on Biotechnology and Health Care. Kairos Ventures invests in ideas, patents, and businesses from the top universities and scientists. Kairos Venture Investments works to get science into the hands of applicable companies.Their team possesses an extraordinary passion to have a huge impact on our world through the creation of companies that will improve our lives and that of thegenerations that will follow. They aim to do this by backing the very best scientists, engineers and entrepreneurs and help them transform their knowledge, ideas and discoveries into viable businesses. They expect these companies to have a huge impact on the world and create significant returns for their shareholders.

## Contacts

5 contacts available for Kairos Ventures. Shizune tracks 17 team members at Kairos Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/kairos-venture-investments-llc?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.6M–$7.5M |
| Series A | $3.2M–$20M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 18 | 29% |
| Health Care | 17 | 27% |
| Therapeutics | 10 | 16% |
| Medical | 9 | 14% |
| Manufacturing | 9 | 14% |

75 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 21 | 33% |
| Series A | 18 | 29% |
| Funding Round | 8 | 13% |
| Series B | 4 | 6% |
| Debt Financing | 2 | 3% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 43 | 68% |
| India | 1 | 2% |
| Italy | 1 | 2% |
| United Kingdom | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alex Andrianopoulos | Chief R&D Officer | 7 | https://shizune.co/investors/profile/alex-andrianopoulos |
| Andreea Boier | Chief Talent Officer | 0 | https://shizune.co/investors/profile/andreea-boier |
| Carol Kachmer | VP, Accounting | 0 | https://shizune.co/investors/profile/carol-kachmer |
| Danielle Walker | Investor Relations Manager | 0 | https://shizune.co/investors/profile/danielle-walker-0b26 |
| DeeAnna Hampton | Executive Assistant | 0 | https://shizune.co/investors/profile/deeanna-hampton |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Purple Style Labs | Purple Style Labs is an IIT-Bombay graduate and ex-banker with Deutsche. It aspires to be the biggest fashion house of India managing multiple designer brands in the premium, luxury as well as affordable retail segment. | $17M | Debt Financing | Jul 10, 2026 |  |
| Alomana | Alomana is an organization that focuses on harnessing the power of artificial intelligence and data analytics to drive insights and innovation across various industries. They offer a range of services, including data analysis, machine learning model development, and AI-driven solutions tailored to meet the specific needs of their clients. Datasparkemphasizes the importance of data-driven decision-making and works closely with businesses to implement strategies that enhance operational efficiency and improve outcomes. With a commitment to advancing the use of AI and data analytics, Dataspark aims to empower organizations to unlock the full potential of their data and stay competitive in a rapidly changing market. | $4.6M | Seed | Mar 16, 2026 |  |
| Vivodyne | Vivodyne develops lifelike human organs for drug testing and research purposes. The company utilizes robotic systems and artificial intelligence to create realistic human tissues that simulate various organ functions. This innovative approach allows for efficient testing of pharmaceuticals, aiming to replace traditional animal testing methods. Byproducing over 100,000 human tissues in a short timeframe, Vivodyne enhances the predictive accuracy of drug responses in humans. The organization is committed to improving the preclinical drug testing process, providing valuable insights that can lead to more effective therapies. Through its advanced technology, Vivodyne contributes to the evolution of biomedical research and development. | $40M | Series A | May 29, 2025 |  |
| Vivodyne | Vivodyne develops lifelike human organs for drug testing and research purposes. The company utilizes robotic systems and artificial intelligence to create realistic human tissues that simulate various organ functions. This innovative approach allows for efficient testing of pharmaceuticals, aiming to replace traditional animal testing methods. Byproducing over 100,000 human tissues in a short timeframe, Vivodyne enhances the predictive accuracy of drug responses in humans. The organization is committed to improving the preclinical drug testing process, providing valuable insights that can lead to more effective therapies. Through its advanced technology, Vivodyne contributes to the evolution of biomedical research and development. | $38M | Seed | Nov 22, 2023 |  |
| PteroDynamics | PteroDynamics' mission is to improve lives by democratizing transportation using sustainable autonomous vertical takeoff and landing (VTOL) aircraft that reduce humankind's impact on the planet.Advanced Air Mobility promises a better way to move people and things from anywhere to anywhere, but this requires a new breed of moreefficient VTOL aircraft. Since 2017, PteroDynamics has been focused on solving this problem. The Company’s revolutionary patented Transwing aircraft design with wings that fold during flight has significant advantages over all other VTOL designs. | $7.5M | Seed | Feb 28, 2023 |  |
| PteroDynamics | PteroDynamics' mission is to improve lives by democratizing transportation using sustainable autonomous vertical takeoff and landing (VTOL) aircraft that reduce humankind's impact on the planet.Advanced Air Mobility promises a better way to move people and things from anywhere to anywhere, but this requires a new breed of moreefficient VTOL aircraft. Since 2017, PteroDynamics has been focused on solving this problem. The Company’s revolutionary patented Transwing aircraft design with wings that fold during flight has significant advantages over all other VTOL designs. | $7.5M | Seed | Feb 28, 2023 |  |
| Behavioral Signals | Behavioral Signals (Behavioral Signal Technologies, Inc.) develops technology to analyze human behavior from voice data. With AI-MC, their flagship product, enterprises can automatically match each customer to the suited agent, using voice data and emotion AI, and see the overall performance and outcomes of their call center conversations reachhigher levels of profitability |  | Venture - Series Unknown | Apr 04, 2022 |  |
| TULU | TULU is a smart platform and amenity services provider to over 10,000 people in 50 buildings across the United States, Europe and Israel. Founded in 2019, TULU provides urban tenants with on-demand access to hundreds of brand name appliances, grocery staples, micro-mobility and entertainment devices, and more. TULU’s IoT-based modular units arecustomized to provide the most necessary and useful items, while leveraging advanced machine learning tools to analyze behavioral patterns, optimize usage, refine inventory, and create a personalized experience for our users. The outcome is a new way of living, encouraging more responsible consumption, reducing the cost of living in the city, and consistent with the trend to smaller and smaller living spaces. | $3M | Seed | Apr 13, 2021 |  |
| Vivodyne | Vivodyne develops lifelike human organs for drug testing and research purposes. The company utilizes robotic systems and artificial intelligence to create realistic human tissues that simulate various organ functions. This innovative approach allows for efficient testing of pharmaceuticals, aiming to replace traditional animal testing methods. Byproducing over 100,000 human tissues in a short timeframe, Vivodyne enhances the predictive accuracy of drug responses in humans. The organization is committed to improving the preclinical drug testing process, providing valuable insights that can lead to more effective therapies. Through its advanced technology, Vivodyne contributes to the evolution of biomedical research and development. | $2M |  | Mar 11, 2021 |  |
| Vivodyne | Vivodyne develops lifelike human organs for drug testing and research purposes. The company utilizes robotic systems and artificial intelligence to create realistic human tissues that simulate various organ functions. This innovative approach allows for efficient testing of pharmaceuticals, aiming to replace traditional animal testing methods. Byproducing over 100,000 human tissues in a short timeframe, Vivodyne enhances the predictive accuracy of drug responses in humans. The organization is committed to improving the preclinical drug testing process, providing valuable insights that can lead to more effective therapies. Through its advanced technology, Vivodyne contributes to the evolution of biomedical research and development. | $2M | Seed | Mar 11, 2021 |  |

10 of 63 investments shown.

## Co-investors
- [CS Venture Opportunities Fund](https://shizune.co/investors/profile/cs-venture-opportunities-fund) — VC Fund, 4 deals together
- [Everywhere Ventures](https://shizune.co/investors/profile/everywhere-ventures) — VC Fund, 3 deals together
- [Spruce Capital Partners](https://shizune.co/investors/profile/spruce-capital-partners) — VC Fund, 3 deals together
- [Aliment Capital](https://shizune.co/investors/profile/aliment-capital) — VC Fund, 2 deals together
- [BASF Venture Capital](https://shizune.co/investors/profile/basf-venture-capital) — VC Fund, 2 deals together
- [Bios Partners](https://shizune.co/investors/profile/bios-partners) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [CDP Venture Capital](https://shizune.co/investors/profile/cdp-venture-capital) — VC Fund
- [Club degli Investitori](https://shizune.co/investors/profile/club-degli-investitori) — VC Fund
- [Primo Capital](https://shizune.co/investors/profile/barcamper-ventures) — VC Fund

## Featured in investor lists
- [Renewable Energy Investors in United States](https://shizune.co/investors/renewable-energy-investors-united-states)
- [Renewable Energy VC Funds in United States](https://shizune.co/investors/renewable-energy-vc-funds-united-states)
- [Life Science Investors in Italy](https://shizune.co/investors/life-science-investors-italy)
- [Life Science VC Funds in Italy](https://shizune.co/investors/life-science-vc-funds-italy)
- [Oil and Gas Investors in Italy](https://shizune.co/investors/oil-and-gas-investors-italy)
- [Oil and Gas VC Funds in Italy](https://shizune.co/investors/oil-and-gas-vc-funds-italy)

## FAQ

### What does Kairos Ventures invest in?

Kairos Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Seed and Series A stage. Most of the 63 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Kairos Ventures's check size?

Kairos Ventures typically joins rounds of $1.6M–$7.5M at Seed and $3.2M–$20M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Kairos Ventures participates in.

### How do I contact Kairos Ventures?

Public channels for Kairos Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Kairos Ventures?

The team at Kairos Ventures includes Alex Andrianopoulos (Chief R&D Officer), Andreea Boier (Chief Talent Officer) and Carol Kachmer (VP, Accounting), among 17 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co